Experience
Founders Fund Co-Leads Anduril’s $1.5 Billion Series F
August 7, 2024
Cooley advised Founders Fund, a venture capital firm investing in smart people solving difficult problems, as a co-lead investor in Anduril Industries’ $1.5 billion Series F funding round, which increased Anduril’s valuation to $14 billion.
Related contacts
Related Practices & Industries
Silvaco Announces $114 Million IPO
May 13, 2024
Cooley advised the underwriters of Silvaco, a leading provider of technology computer-aided design (TCAD), electronic design animation (EDA) software, and session initiation protocol (SIP) solutions that enable semiconductor design and artificial intelligence through software and innovation, on its $114 million initial public offering.
Related contacts
Related Practices & Industries
Carmot Therapeutics Enters Definitive Merger Agreement With Roche
December 3, 2023
Cooley advised Carmot Therapeutics, a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, on its definitive merger agreement in which Roche will acquire Carmot.
Related contacts
Related Practices & Industries
Turnstone Biologics Announces Upsized $80 Million IPO
July 26, 2023
Cooley advised Turnstone Biologics, a clinical-stage biotechnology company, on its upsized $80 million initial public offering.
Related contacts
Related Practices & Industries
ACELYRIN Announces Pricing of Upsized Initial Public Offering
May 15, 2023
Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.
Related contacts
Related Practices & Industries
Related news and events
Admissions and credentials
California
Washington